Literature DB >> 23940218

Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Aaron R Weiss1, Elizabeth R Lyden, James R Anderson, Douglas S Hawkins, Sheri L Spunt, David O Walterhouse, Suzanne L Wolden, David M Parham, David A Rodeberg, Simon C Kao, Richard B Womer.   

Abstract

PURPOSE: To simplify the recommended staging evaluation by correlating tumor and clinical features with patterns of distant metastasis in newly diagnosed patients with embryonal rhabdomyosarcoma (ERMS) or alveolar rhabdomyosarcoma (ARMS). PATIENTS AND METHODS: Patient data from the Intergroup Rhabdomyosarcoma Study Group and the Children's Oncology Group over two periods were analyzed: 1991 to 1997 and 1999 to 2004. We used recursive partitioning analyses to identify factors (including histology, age, regional nodal and distant metastatic status, tumor size, local invasiveness, and primary site) that divided patients into subsets with the most different rates of metastatic disease.
RESULTS: Of the 1,687 patients analyzed, 5.7% had lung metastases, 4.8% had bone involvement, and 6% had bone marrow (BM) involvement. Rhabdomyosarcoma (RMS) without local invasion (T1) had a low rate of metastasis for all distant sites, especially ERMS (0% bone, 0% BM). ARMS with local invasion (T2) had a higher rate of metastasis for all distant sites (13% lung, 18% bone, 23% BM). ERMS, T2 also had a higher rate of metastatic lung involvement (9%). The likelihood of bone or BM involvement increased in the presence of lung metastases (41% with, 6% without). Regional nodal metastases (N1) predicted a high rate of metastasis in all distant sites (14% lung, 14% bone, 18% BM). A staging algorithm was developed.
CONCLUSION: Staging studies in childhood RMS can be tailored to patients' presenting characteristics. Bone marrow aspirate and biopsy and bone scan are unnecessary in at least one third of patients with RMS.

Entities:  

Mesh:

Year:  2013        PMID: 23940218      PMCID: PMC3757291          DOI: 10.1200/JCO.2012.44.6476

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  31 in total

1.  Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group.

Authors:  W Lawrence; J R Anderson; E A Gehan; H Maurer
Journal:  Cancer       Date:  1997-09-15       Impact factor: 6.860

2.  Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee.

Authors:  W M Crist; L Garnsey; M S Beltangady; E Gehan; F Ruymann; B Webber; D M Hays; M Wharam; H M Maurer
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

3.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

Authors:  Poul H B Sorensen; James C Lynch; Stephen J Qualman; Roberto Tirabosco; Jerian F Lim; Harold M Maurer; Julia A Bridge; William M Crist; Timothy J Triche; Frederic G Barr
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma.

Authors:  Fabien Ricard; Sébastien Cimarelli; Emmanuel Deshayes; Thomas Mognetti; Philippe Thiesse; Francesco Giammarile
Journal:  Clin Nucl Med       Date:  2011-08       Impact factor: 7.794

5.  European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.

Authors:  M Carli; R Colombatti; O Oberlin; G Bisogno; J Treuner; E Koscielniak; G Tridello; A Garaventa; R Pinkerton; M Stevens
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

6.  Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.

Authors:  David O Walterhouse; Elizabeth R Lyden; Philip P Breitfeld; Stephen J Qualman; Moody D Wharam; William H Meyer
Journal:  J Clin Oncol       Date:  2004-03-08       Impact factor: 44.544

7.  The Intergroup Rhabdomyosarcoma Study-II.

Authors:  H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

8.  The Intergroup Rhabdomyosarcoma Study-I. A final report.

Authors:  H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

9.  Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  D Joshi; James R Anderson; C Paidas; J Breneman; D M Parham; W Crist
Journal:  Pediatr Blood Cancer       Date:  2004-01       Impact factor: 3.167

10.  The Third Intergroup Rhabdomyosarcoma Study.

Authors:  W Crist; E A Gehan; A H Ragab; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann; R Heyn
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

View more
  31 in total

1.  Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David O Walterhouse; Alberto S Pappo; Jane L Meza; John C Breneman; Andrea A Hayes-Jordan; David M Parham; Timothy P Cripe; James R Anderson; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 2.  Head and neck rhabdomyosarcoma: follow-up results of four cases and review of the literature.

Authors:  Dong-Ni Zhou; Qing-Qing Yang; Zhong-Lin Li; Zhi-Yong Pan; Yan-Fei Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  What is new in the biology and treatment of pediatric rhabdomyosarcoma?

Authors:  Douglas S Hawkins; Abha A Gupta; Erin R Rudzinski
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

4.  Identification of Discrete Prognostic Groups in Ewing Sarcoma.

Authors:  Erin E Karski; Elizabeth McIlvaine; Mark R Segal; Mark Krailo; Holcombe E Grier; Linda Granowetter; Richard B Womer; Paul A Meyers; Judy Felgenhauer; Neyssa Marina; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2015-08-10       Impact factor: 3.167

5.  Clinical characteristics and prognosis of childhood rhabdomyosarcoma: a ten-year retrospective multicenter study.

Authors:  Xiaoli Ma; Dongsheng Huang; Weihong Zhao; Liming Sun; Hao Xiong; Yi Zhang; Mei Jin; Dawei Zhang; Cheng Huang; Huanmin Wang; Weiping Zhang; Ning Sun; Lejian He; Jingyan Tang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

6.  A leukemic presentation of alveolar rhabdomyosarcoma in a 52-year-old woman without an identifiable primary tumor.

Authors:  Jason B Kern; Anselm Hii; Matthew J Kruse; Zsolt Szabo; Pedram Argani; Michele K Hibbard; Douglas E Gladstone; Christian Meyer; Rui Zheng; Michael J Borowitz; Amy S Duffield
Journal:  Int J Surg Pathol       Date:  2014-10-10       Impact factor: 1.271

7.  Embryonal rhabdomyosarcoma of the epididymis presenting as epididymitis: A case report.

Authors:  Hong-Liang Wang; Ling-Yun Liu; Run-Hui Tian; Fu-Biao Li; Kai-Min Guo
Journal:  Mol Clin Oncol       Date:  2016-01-18

Review 8.  The clinical and radiologic features of paediatric rhabdomyosarcoma.

Authors:  Noorulhuda Jawad; Kieran McHugh
Journal:  Pediatr Radiol       Date:  2019-10-16

9.  The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients.

Authors:  Alaa Elmanzalawy; Reza Vali; Govind B Chavhan; Abha A Gupta; Yusuf Omarkhail; Afsaneh Amirabadi; Amer Shammas
Journal:  Pediatr Radiol       Date:  2019-10-18

10.  GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma.

Authors:  S Gallego; D Bernabeu; M Garrido-Pontnou; G Guillen; N Hindi; A Juan-Ribelles; C Márquez; C Mata; J Orcajo; G Ramírez; M Ramos; C Romagosa; D Ruano; P Rubio; R Vergés; C Valverde
Journal:  Clin Transl Oncol       Date:  2021-07-01       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.